New Frontier Health Corporation
New Frontier Health Corporation (NFH) Stock Competitors & Peer Comparison
See (NFH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NFH | $11.95 | +0.25% | 0 | -19.75 | -$0.61 | N/A |
| HCA | $428.79 | +0.38% | 95.1B | 14.98 | $28.62 | +0.68% |
| THC | $186.91 | +0.84% | 16.4B | 9.72 | $19.23 | N/A |
| SOLV | $69.04 | +2.37% | 12B | 7.78 | $8.88 | N/A |
| FMS | $20.19 | -10.86% | 11.3B | 10.19 | $1.98 | +4.03% |
| EHC | $105.16 | -1.39% | 10.5B | 18.01 | $5.84 | +0.70% |
| DVA | $157.04 | +1.92% | 10.4B | 16.51 | $9.51 | N/A |
| UHS | $165.40 | -0.40% | 10.4B | 6.90 | $23.95 | +0.48% |
| ENSG | $175.95 | -3.34% | 10.3B | 28.71 | $6.13 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
NFH vs HCA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, HCA has a market cap of 95.1B. Regarding current trading prices, NFH is priced at $11.95, while HCA trades at $428.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas HCA's P/E ratio is 14.98. In terms of profitability, NFH's ROE is -0.06%, compared to HCA's ROE of -1.23%. Regarding short-term risk, NFH is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check HCA's competition here
NFH vs THC Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, THC has a market cap of 16.4B. Regarding current trading prices, NFH is priced at $11.95, while THC trades at $186.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas THC's P/E ratio is 9.72. In terms of profitability, NFH's ROE is -0.06%, compared to THC's ROE of +0.41%. Regarding short-term risk, NFH is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check THC's competition here
NFH vs SOLV Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SOLV has a market cap of 12B. Regarding current trading prices, NFH is priced at $11.95, while SOLV trades at $69.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SOLV's P/E ratio is 7.78. In terms of profitability, NFH's ROE is -0.06%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, NFH is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check SOLV's competition here
NFH vs FMS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, FMS has a market cap of 11.3B. Regarding current trading prices, NFH is priced at $11.95, while FMS trades at $20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas FMS's P/E ratio is 10.19. In terms of profitability, NFH's ROE is -0.06%, compared to FMS's ROE of +0.07%. Regarding short-term risk, NFH is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check FMS's competition here
NFH vs EHC Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, EHC has a market cap of 10.5B. Regarding current trading prices, NFH is priced at $11.95, while EHC trades at $105.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas EHC's P/E ratio is 18.01. In terms of profitability, NFH's ROE is -0.06%, compared to EHC's ROE of +0.25%. Regarding short-term risk, NFH is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check EHC's competition here
NFH vs DVA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, DVA has a market cap of 10.4B. Regarding current trading prices, NFH is priced at $11.95, while DVA trades at $157.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas DVA's P/E ratio is 16.51. In terms of profitability, NFH's ROE is -0.06%, compared to DVA's ROE of -1.61%. Regarding short-term risk, NFH is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check DVA's competition here
NFH vs UHS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, UHS has a market cap of 10.4B. Regarding current trading prices, NFH is priced at $11.95, while UHS trades at $165.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas UHS's P/E ratio is 6.90. In terms of profitability, NFH's ROE is -0.06%, compared to UHS's ROE of +0.21%. Regarding short-term risk, NFH is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check UHS's competition here
NFH vs ENSG Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ENSG has a market cap of 10.3B. Regarding current trading prices, NFH is priced at $11.95, while ENSG trades at $175.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ENSG's P/E ratio is 28.71. In terms of profitability, NFH's ROE is -0.06%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, NFH is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ENSG's competition here
NFH vs OSH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, NFH is priced at $11.95, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas OSH's P/E ratio is -17.65. In terms of profitability, NFH's ROE is -0.06%, compared to OSH's ROE of +4.64%. Regarding short-term risk, NFH is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check OSH's competition here
NFH vs CHE Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CHE has a market cap of 5.7B. Regarding current trading prices, NFH is priced at $11.95, while CHE trades at $427.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CHE's P/E ratio is 23.36. In terms of profitability, NFH's ROE is -0.06%, compared to CHE's ROE of +0.25%. Regarding short-term risk, NFH is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CHE's competition here
NFH vs LHCG Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, NFH is priced at $11.95, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas LHCG's P/E ratio is 82.83. In terms of profitability, NFH's ROE is -0.06%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, NFH is less volatile compared to LHCG. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check LHCG's competition here
NFH vs BKD Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, BKD has a market cap of 3.3B. Regarding current trading prices, NFH is priced at $11.95, while BKD trades at $14.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas BKD's P/E ratio is -12.52. In terms of profitability, NFH's ROE is -0.06%, compared to BKD's ROE of -5.24%. Regarding short-term risk, NFH is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check BKD's competition here
NFH vs OPCH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, OPCH has a market cap of 3.3B. Regarding current trading prices, NFH is priced at $11.95, while OPCH trades at $21.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas OPCH's P/E ratio is 16.64. In terms of profitability, NFH's ROE is -0.06%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, NFH is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check OPCH's competition here
NFH vs AMED Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, NFH is priced at $11.95, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AMED's P/E ratio is 39.30. In terms of profitability, NFH's ROE is -0.06%, compared to AMED's ROE of +0.09%. Regarding short-term risk, NFH is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check AMED's competition here
NFH vs MMED Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, MMED has a market cap of 3.3B. Regarding current trading prices, NFH is priced at $11.95, while MMED trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas MMED's P/E ratio is -9.27. In terms of profitability, NFH's ROE is -0.06%, compared to MMED's ROE of -0.09%. Regarding short-term risk, NFH is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check MMED's competition here
NFH vs LFST Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, LFST has a market cap of 2.8B. Regarding current trading prices, NFH is priced at $11.95, while LFST trades at $7.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas LFST's P/E ratio is 367.00. In terms of profitability, NFH's ROE is -0.06%, compared to LFST's ROE of +0.01%. Regarding short-term risk, NFH is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check LFST's competition here
NFH vs NHC Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, NHC has a market cap of 2.6B. Regarding current trading prices, NFH is priced at $11.95, while NHC trades at $167.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas NHC's P/E ratio is 21.70. In terms of profitability, NFH's ROE is -0.06%, compared to NHC's ROE of +0.12%. Regarding short-term risk, NFH is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check NHC's competition here
NFH vs ACHC Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ACHC has a market cap of 2.3B. Regarding current trading prices, NFH is priced at $11.95, while ACHC trades at $25.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ACHC's P/E ratio is -2.07. In terms of profitability, NFH's ROE is -0.06%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, NFH is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ACHC's competition here
NFH vs SEM Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SEM has a market cap of 2B. Regarding current trading prices, NFH is priced at $11.95, while SEM trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SEM's P/E ratio is 15.37. In terms of profitability, NFH's ROE is -0.06%, compared to SEM's ROE of +0.08%. Regarding short-term risk, NFH is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check SEM's competition here
NFH vs ASTH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ASTH has a market cap of 2B. Regarding current trading prices, NFH is priced at $11.95, while ASTH trades at $35.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ASTH's P/E ratio is 76.54. In terms of profitability, NFH's ROE is -0.06%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, NFH is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ASTH's competition here
NFH vs SGRY Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, NFH is priced at $11.95, while SGRY trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SGRY's P/E ratio is -23.38. In terms of profitability, NFH's ROE is -0.06%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, NFH is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check SGRY's competition here
NFH vs ADUS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ADUS has a market cap of 1.8B. Regarding current trading prices, NFH is priced at $11.95, while ADUS trades at $98.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ADUS's P/E ratio is 18.83. In terms of profitability, NFH's ROE is -0.06%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, NFH is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ADUS's competition here
NFH vs AMEH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, NFH is priced at $11.95, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AMEH's P/E ratio is 39.25. In terms of profitability, NFH's ROE is -0.06%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, NFH is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AMEH's competition here
NFH vs MD Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, NFH is priced at $11.95, while MD trades at $20.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas MD's P/E ratio is 10.74. In terms of profitability, NFH's ROE is -0.06%, compared to MD's ROE of +0.20%. Regarding short-term risk, NFH is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check MD's competition here
NFH vs HCSG Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, NFH is priced at $11.95, while HCSG trades at $21.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas HCSG's P/E ratio is 22.86. In terms of profitability, NFH's ROE is -0.06%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, NFH is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check HCSG's competition here
NFH vs ARDT Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ARDT has a market cap of 1.5B. Regarding current trading prices, NFH is priced at $11.95, while ARDT trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ARDT's P/E ratio is 10.56. In terms of profitability, NFH's ROE is -0.06%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, NFH is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ARDT's competition here
NFH vs AVAH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, NFH is priced at $11.95, while AVAH trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AVAH's P/E ratio is 6.16. In terms of profitability, NFH's ROE is -0.06%, compared to AVAH's ROE of +9.53%. Regarding short-term risk, NFH is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AVAH's competition here
NFH vs BKDT Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, NFH is priced at $11.95, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas BKDT's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, NFH is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check BKDT's competition here
NFH vs PNTG Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, NFH is priced at $11.95, while PNTG trades at $31.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas PNTG's P/E ratio is 37.45. In terms of profitability, NFH's ROE is -0.06%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, NFH is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check PNTG's competition here
NFH vs USPH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, USPH has a market cap of 1.1B. Regarding current trading prices, NFH is priced at $11.95, while USPH trades at $71.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas USPH's P/E ratio is 50.42. In terms of profitability, NFH's ROE is -0.06%, compared to USPH's ROE of +0.03%. Regarding short-term risk, NFH is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check USPH's competition here
NFH vs INNV Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, NFH is priced at $11.95, while INNV trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas INNV's P/E ratio is 159.00. In terms of profitability, NFH's ROE is -0.06%, compared to INNV's ROE of -0.02%. Regarding short-term risk, NFH is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check INNV's competition here
NFH vs FSHCX Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, FSHCX has a market cap of 919.8M. Regarding current trading prices, NFH is priced at $11.95, while FSHCX trades at $103.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas FSHCX's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to FSHCX's ROE of N/A. Regarding short-term risk, NFH is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check FSHCX's competition here
NFH vs CMPS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CMPS has a market cap of 895.5M. Regarding current trading prices, NFH is priced at $11.95, while CMPS trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CMPS's P/E ratio is -3.03. In terms of profitability, NFH's ROE is -0.06%, compared to CMPS's ROE of -3.36%. Regarding short-term risk, NFH is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CMPS's competition here
NFH vs TALK Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, NFH is priced at $11.95, while TALK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TALK's P/E ratio is 130.00. In terms of profitability, NFH's ROE is -0.06%, compared to TALK's ROE of +0.07%. Regarding short-term risk, NFH is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check TALK's competition here
NFH vs AMN Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AMN has a market cap of 823.4M. Regarding current trading prices, NFH is priced at $11.95, while AMN trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AMN's P/E ratio is -8.59. In terms of profitability, NFH's ROE is -0.06%, compared to AMN's ROE of -0.15%. Regarding short-term risk, NFH is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AMN's competition here
NFH vs EHAB Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, EHAB has a market cap of 704.1M. Regarding current trading prices, NFH is priced at $11.95, while EHAB trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas EHAB's P/E ratio is -152.72. In terms of profitability, NFH's ROE is -0.06%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, NFH is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check EHAB's competition here
NFH vs SNDA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SNDA has a market cap of 674.8M. Regarding current trading prices, NFH is priced at $11.95, while SNDA trades at $37.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SNDA's P/E ratio is -8.86. In terms of profitability, NFH's ROE is -0.06%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, NFH is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check SNDA's competition here
NFH vs MCTA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, NFH is priced at $11.95, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas MCTA's P/E ratio is 419.36. In terms of profitability, NFH's ROE is -0.06%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, NFH is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check MCTA's competition here
NFH vs AGL Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AGL has a market cap of 444.2M. Regarding current trading prices, NFH is priced at $11.95, while AGL trades at $26.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AGL's P/E ratio is -1.09. In terms of profitability, NFH's ROE is -0.06%, compared to AGL's ROE of -1.17%. Regarding short-term risk, NFH is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AGL's competition here
NFH vs CYH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CYH has a market cap of 398.1M. Regarding current trading prices, NFH is priced at $11.95, while CYH trades at $2.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CYH's P/E ratio is 0.82. In terms of profitability, NFH's ROE is -0.06%, compared to CYH's ROE of +0.06%. Regarding short-term risk, NFH is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CYH's competition here
NFH vs TOI Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TOI has a market cap of 393.4M. Regarding current trading prices, NFH is priced at $11.95, while TOI trades at $3.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TOI's P/E ratio is -7.37. In terms of profitability, NFH's ROE is -0.06%, compared to TOI's ROE of +7.60%. Regarding short-term risk, NFH is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check TOI's competition here
NFH vs AUNA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AUNA has a market cap of 372.3M. Regarding current trading prices, NFH is priced at $11.95, while AUNA trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AUNA's P/E ratio is 13.59. In terms of profitability, NFH's ROE is -0.06%, compared to AUNA's ROE of +0.06%. Regarding short-term risk, NFH is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AUNA's competition here
NFH vs CCRN Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CCRN has a market cap of 345.2M. Regarding current trading prices, NFH is priced at $11.95, while CCRN trades at $10.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CCRN's P/E ratio is -3.65. In terms of profitability, NFH's ROE is -0.06%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, NFH is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CCRN's competition here
NFH vs AONC Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AONC has a market cap of 263.2M. Regarding current trading prices, NFH is priced at $11.95, while AONC trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AONC's P/E ratio is -10.11. In terms of profitability, NFH's ROE is -0.06%, compared to AONC's ROE of +0.06%. Regarding short-term risk, NFH is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check AONC's competition here
NFH vs AIRS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AIRS has a market cap of 250.1M. Regarding current trading prices, NFH is priced at $11.95, while AIRS trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AIRS's P/E ratio is -18.66. In terms of profitability, NFH's ROE is -0.06%, compared to AIRS's ROE of -0.14%. Regarding short-term risk, NFH is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AIRS's competition here
NFH vs CSU Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, NFH is priced at $11.95, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CSU's P/E ratio is 0.67. In terms of profitability, NFH's ROE is -0.06%, compared to CSU's ROE of -2.10%. Regarding short-term risk, NFH is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CSU's competition here
NFH vs JYNT Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, JYNT has a market cap of 123.7M. Regarding current trading prices, NFH is priced at $11.95, while JYNT trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas JYNT's P/E ratio is -432.00. In terms of profitability, NFH's ROE is -0.06%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, NFH is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check JYNT's competition here
NFH vs NAKAW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, NFH is priced at $11.95, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas NAKAW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to NAKAW's ROE of -0.21%. Regarding short-term risk, NFH is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check NAKAW's competition here
NFH vs FVE Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, NFH is priced at $11.95, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas FVE's P/E ratio is -5.64. In terms of profitability, NFH's ROE is -0.06%, compared to FVE's ROE of -0.15%. Regarding short-term risk, NFH is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check FVE's competition here
NFH vs BTMD Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, BTMD has a market cap of 97M. Regarding current trading prices, NFH is priced at $11.95, while BTMD trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas BTMD's P/E ratio is 2.97. In terms of profitability, NFH's ROE is -0.06%, compared to BTMD's ROE of -0.35%. Regarding short-term risk, NFH is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check BTMD's competition here
NFH vs KDLYW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, NFH is priced at $11.95, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas KDLYW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to KDLYW's ROE of -0.21%. Regarding short-term risk, NFH is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check KDLYW's competition here
NFH vs DCGO Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, DCGO has a market cap of 67.5M. Regarding current trading prices, NFH is priced at $11.95, while DCGO trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas DCGO's P/E ratio is -0.37. In terms of profitability, NFH's ROE is -0.06%, compared to DCGO's ROE of -0.71%. Regarding short-term risk, NFH is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check DCGO's competition here
NFH vs ALR Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, NFH is priced at $11.95, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ALR's P/E ratio is -1.11. In terms of profitability, NFH's ROE is -0.06%, compared to ALR's ROE of -0.15%. Regarding short-term risk, NFH is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ALR's competition here
NFH vs IMAC Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, NFH is priced at $11.95, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas IMAC's P/E ratio is -2.27. In terms of profitability, NFH's ROE is -0.06%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, NFH is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check IMAC's competition here
NFH vs CCEL Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CCEL has a market cap of 28.8M. Regarding current trading prices, NFH is priced at $11.95, while CCEL trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CCEL's P/E ratio is -11.19. In terms of profitability, NFH's ROE is -0.06%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, NFH is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CCEL's competition here
NFH vs CANO-WT Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, NFH is priced at $11.95, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, NFH is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CANO-WT's competition here
NFH vs AIH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, NFH is priced at $11.95, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AIH's P/E ratio is -2.78. In terms of profitability, NFH's ROE is -0.06%, compared to AIH's ROE of +1.16%. Regarding short-term risk, NFH is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AIH's competition here
NFH vs CANO Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, NFH is priced at $11.95, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CANO's P/E ratio is -0.01. In terms of profitability, NFH's ROE is -0.06%, compared to CANO's ROE of -1.49%. Regarding short-term risk, NFH is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CANO's competition here
NFH vs AMS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AMS has a market cap of 11.6M. Regarding current trading prices, NFH is priced at $11.95, while AMS trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AMS's P/E ratio is -7.63. In terms of profitability, NFH's ROE is -0.06%, compared to AMS's ROE of -0.06%. Regarding short-term risk, NFH is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AMS's competition here
NFH vs FTRP Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, NFH is priced at $11.95, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas FTRP's P/E ratio is -1.22. In terms of profitability, NFH's ROE is -0.06%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, NFH is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check FTRP's competition here
NFH vs PIII Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, PIII has a market cap of 9.5M. Regarding current trading prices, NFH is priced at $11.95, while PIII trades at $2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas PIII's P/E ratio is -0.06. In terms of profitability, NFH's ROE is -0.06%, compared to PIII's ROE of +8.94%. Regarding short-term risk, NFH is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check PIII's competition here
NFH vs MODV Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, NFH is priced at $11.95, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas MODV's P/E ratio is -0.03. In terms of profitability, NFH's ROE is -0.06%, compared to MODV's ROE of +1.84%. Regarding short-term risk, NFH is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check MODV's competition here
NFH vs GBNH Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, NFH is priced at $11.95, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas GBNH's P/E ratio is -0.06. In terms of profitability, NFH's ROE is -0.06%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, NFH is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check GBNH's competition here
NFH vs RHE-PA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, NFH is priced at $11.95, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, NFH's ROE is -0.06%, compared to RHE-PA's ROE of -9.49%. Regarding short-term risk, NFH is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check RHE-PA's competition here
NFH vs RHE Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, NFH is priced at $11.95, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas RHE's P/E ratio is -1.79. In terms of profitability, NFH's ROE is -0.06%, compared to RHE's ROE of -0.00%. Regarding short-term risk, NFH is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check RHE's competition here
NFH vs SYRA Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SYRA has a market cap of 5.1M. Regarding current trading prices, NFH is priced at $11.95, while SYRA trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SYRA's P/E ratio is -5.58. In terms of profitability, NFH's ROE is -0.06%, compared to SYRA's ROE of -0.39%. Regarding short-term risk, NFH is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check SYRA's competition here
NFH vs TOIIW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TOIIW has a market cap of 3.9M. Regarding current trading prices, NFH is priced at $11.95, while TOIIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TOIIW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, NFH is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check TOIIW's competition here
NFH vs ATIP Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, NFH is priced at $11.95, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ATIP's P/E ratio is -0.03. In terms of profitability, NFH's ROE is -0.06%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, NFH is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ATIP's competition here
NFH vs IMACW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, NFH is priced at $11.95, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas IMACW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, NFH is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check IMACW's competition here
NFH vs MNDR Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, MNDR has a market cap of 969.9K. Regarding current trading prices, NFH is priced at $11.95, while MNDR trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas MNDR's P/E ratio is -0.36. In terms of profitability, NFH's ROE is -0.06%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, NFH is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check MNDR's competition here
NFH vs CCM Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, CCM has a market cap of 658.2K. Regarding current trading prices, NFH is priced at $11.95, while CCM trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas CCM's P/E ratio is -1.45. In terms of profitability, NFH's ROE is -0.06%, compared to CCM's ROE of +0.07%. Regarding short-term risk, NFH is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check CCM's competition here
NFH vs TALKW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TALKW has a market cap of 268K. Regarding current trading prices, NFH is priced at $11.95, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TALKW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, NFH is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check TALKW's competition here
NFH vs BACK Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, BACK has a market cap of 147.6K. Regarding current trading prices, NFH is priced at $11.95, while BACK trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas BACK's P/E ratio is -0.01. In terms of profitability, NFH's ROE is -0.06%, compared to BACK's ROE of +1.05%. Regarding short-term risk, NFH is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check BACK's competition here
NFH vs NVOS Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, NVOS has a market cap of 61.2K. Regarding current trading prices, NFH is priced at $11.95, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas NVOS's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, NFH is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check NVOS's competition here
NFH vs NIVFW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, NIVFW has a market cap of 52.3K. Regarding current trading prices, NFH is priced at $11.95, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas NIVFW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, NFH is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check NIVFW's competition here
NFH vs PIIIW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, PIIIW has a market cap of 16.3K. Regarding current trading prices, NFH is priced at $11.95, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas PIIIW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to PIIIW's ROE of +8.94%. Regarding short-term risk, NFH is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check PIIIW's competition here
NFH vs IONM Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, NFH is priced at $11.95, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas IONM's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to IONM's ROE of +5.28%. Regarding short-term risk, NFH is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check IONM's competition here
NFH vs KND Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, KND has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas KND's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to KND's ROE of -0.53%. Regarding short-term risk, NFH is less volatile compared to KND. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check KND's competition here
NFH vs TLMD Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TLMD has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TLMD's P/E ratio is -1.60. In terms of profitability, NFH's ROE is -0.06%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, NFH is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check TLMD's competition here
NFH vs ATIP-WT Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, NFH is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check ATIP-WT's competition here
NFH vs TVTY Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TVTY has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TVTY's P/E ratio is 19.06. In terms of profitability, NFH's ROE is -0.06%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, NFH is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check TVTY's competition here
NFH vs SLHGP Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, NFH's ROE is -0.06%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, NFH is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check SLHGP's competition here
NFH vs AFAM Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, AFAM has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas AFAM's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, NFH is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check AFAM's competition here
NFH vs HNGR Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, HNGR has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas HNGR's P/E ratio is 19.71. In terms of profitability, NFH's ROE is -0.06%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, NFH is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for NFH.Check HNGR's competition here
NFH vs TLMDW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas TLMDW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, NFH is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check TLMDW's competition here
NFH vs DVCR Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, DVCR has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas DVCR's P/E ratio is 28.34. In terms of profitability, NFH's ROE is -0.06%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, NFH is less volatile compared to DVCR. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check DVCR's competition here
NFH vs SLHG Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, SLHG has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas SLHG's P/E ratio is -1.48. In terms of profitability, NFH's ROE is -0.06%, compared to SLHG's ROE of N/A. Regarding short-term risk, NFH is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check SLHG's competition here
NFH vs DCGOW Comparison May 2026
NFH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NFH stands at 0. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, NFH is priced at $11.95, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NFH currently has a P/E ratio of -19.75, whereas DCGOW's P/E ratio is N/A. In terms of profitability, NFH's ROE is -0.06%, compared to DCGOW's ROE of -0.71%. Regarding short-term risk, NFH is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for NFH.Check DCGOW's competition here